Accelerated treatment of COVID-19 and SAR's type viruses

Abstract

Inhalation Via Nebulized Aerosol of Designed solution mixture of 1.8 to 3.7% Hypertonic saline 70 to 85% Ethanol as solvent alternating with 10 milliliters 50 to 90% Theobromine alternatively I.V. Theobromine “c7H8N4O2” infusion alternating with inhaled nebulized exogenous Pulmonary surfactant replacement. The inhalation alternating as an I.V. solution or 1.8% to 2.2% hypertonic solution in Theobromine as 450 mg to 650 mg. in Ethanol, twice daily for advanced COVID-19, SARS patients.

1 . I claim a specifically designed solution-mixture used either inhaled and or intravenous route as a treatment of Acute and or Chronic respiratory distress brought on by invasion by COVID-19 and or SAR's type viruses, and or any associated sub-variants arising and or secondary bacterial infection as treatment. 
     
     
         2 . I claim the usage of a uniquely designed for less dense gaseous mixture composed of the herein “oxygen enriched air mixed with helium” gases for purposes of providing aerosolization of the solution-mixture and medicines achieving greater depth of penetration in medical and non-medical aerosol administration usage by inhalation. 
     
     
         3 . I claim dependent upon  claim 2  the greater ability of surfactant replacement by usage of less dense oxygen rich air with helium to provide greater spread in shorter times for usage in those with airways disease by damaged surfactant pools or by deficient surfactant pools, making it harder to breath due to greater surface tension in those individuals effected by dysfunction or deficient surfactant pools. 
     
     
         4 . I claim dependent upon  claim 1  above, said solution mixture may be used for any individual presenting with ARDS (“Acute Respiratory Distress Syndrome”) or CRDS (“Chronic Respiratory Distress Syndrome”) caused by any viral and or secondary bacterial condition, this as a medical treatment. 
     
     
         5 . I claim as dependent upon  claim 4  above said solution mixture used as a prophylactic for COVID-19 variant's that arise in the course of transmission variables and or other circumstance's that cause viral mutations to arise in the course of this pandemic and or any other endemic or pandemic state of being. 
     
     
         6 . I claim the usage of theobromine as both a phosphodiesterase inhibitor to modify cytokine storms while simultaneously effecting bronchodilation of airway reduction diameters affected by diseases the like as COPD and or Asthma and or Emphysema. 
     
     
         7 . I claim as dependent claim from claim no.  6  the unique usage of theobromine, either as liquid or powder form for purpose of as cough and cough reflex suppressant that controls coughing without interference with central nervous system regulations as other cough suppressants cause and providing greater suppression and being safer by limiting or removing side effects as seen by other cough suppressants.' 
     
     
         8 . I claim as dependent upon claim No.  1  the usage of a less dense oxygen enriched helium gaseous mixture to effect greater tidal volume of air entry into breathing disabled individual's who have respiratory distress either acute or chronic. 
     
     
         9 . I claim as dependent claim upon claim No.  4 , above the usage of oxygen enriched air with helium mix as a mixture of gases for improving and providing greater depth of aerosolized medication for assisting in breathing, Drugs as antibiotics and or airway diameter openers and or exogenous surfactant replacement administration. 
     
     
         10 . I claim as dependent claim of No.  7  above, the greater benefits above the current arts had by usage of theobromine singularly and in the solution-mixture in application to the airways and lung fields by inhalation, it being both a phosphodiesterase inhibitor and methylxanthine. 
     
     
         11 . I claim as dependent claim of No.  10  above, the greater benefits above the arts in use of theobromine in the solution-mixture, either singularly or in combination by the theobromine additive as a methylxanthine and as a phosphodiesterase inhibitor allows for a milder relaxation of the inflammatory airway diameter constriction. 
     
     
         12 . I claim as dependent claim of No.  11  above, usage of inhaled theobromine in airway dysfunction and or disease additionally combatting the cytokine cascades commonly seen in COVID-19 and SAR's variants.' This where a steroid drug or other anti-inflammatory drug and or medicine would simply not due in enough time and have negative side effects. Certainly not by the inhalation route. 
     
     
         13 . I claim as independent claim a method of attack upon the COVID-19 disease, as a treatment, the only direct airway treatment available to date, that challenges the conscription and merging of COVID-19-of all variant's arising-typically causing infiltration and inflammation to the both airways and lungs as its delicate alveolar-capillary membrane with combined resulting pneumonias and oxygen diffusion blockades. 
     
     
         14 . I claim as extension and dependent upon claim No. 11, above the selection of theobromine in the solution-mixture and as single ingredient used as aerosol or in I.V. route would allow several benefits other airway chemicals and or drugs that would not be able to achieve as this present invention does. 
     
     
         15 . I claim as extension of claim No. 2, above the usage of oxygen enriched air mixed with helium” gases to allow easier breathing in those with respiratory problems as seen in patients having Chronic Obstructive Pulmonary Disease (“C.O.P.D.”) and or those individuals for whatever reasons; medical or surgical have difficulty in generating good inspiratory negative draw.